Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) and biopharmaceutical company Pfizer Inc (NYSE:PFE) on Tuesday announced positive data from a Phase 2 study of their Lyme disease vaccine candidate, VLA15.
The study evaluated the immune response and safety profile after a second booster dose.
Results showed a strong immune response and favourable safety profile in all age groups. Seroconversion rates were high, indicating effective protection against Lyme disease.
VLA15 is currently in Phase 3 clinical trials and could potentially be approved in 2026.
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Bavarian Nordic secures additional USD156.8m US government contract
myTomorrows names new director
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
Latigo Biotherapeutics names new chief executive officer
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine